Should Clopidogrel Be Held Before Spinal Injection in an 88-Year-Old Female?
Yes, clopidogrel (Plavix) should be discontinued 7 to 10 days before a spinal injection if it can be done safely, but this decision critically depends on her cardiovascular risk profile and the specific type of spinal injection being performed.
Risk Stratification Framework
The decision to hold clopidogrel hinges on two key assessments:
1. Cardiovascular Risk Assessment
First, determine why this 88-year-old patient is on clopidogrel:
High cardiovascular risk scenarios (where stopping is dangerous):
Lower cardiovascular risk scenarios (where stopping is safer):
- Remote cardiovascular history
- Primary prevention
- Stable coronary disease without recent events
2. Spinal Injection Bleeding Risk Classification
High bleeding risk procedures (neuraxial/epidural space):
- Interlaminar epidural injections (cervical, thoracic, lumbar, caudal)
- These carry the highest risk of epidural hematoma with potential catastrophic neurologic consequences
Lower bleeding risk procedures:
- Transforaminal epidural injections
- Medial branch blocks
- Facet joint injections
- Sacroiliac joint injections
- Radiofrequency ablations
Evidence-Based Recommendations
For High Bleeding Risk Procedures (Interlaminar Epidural)
Clopidogrel should be discontinued 7-10 days before the procedure 1, 2. The FDA label specifically warns to "avoid neuraxial blockade during clopidogrel use because of the risk of spinal hematoma" and recommends discontinuing clopidogrel 5-7 days prior when possible 4.
The AAGBI 2016 guidelines recommend stopping clopidogrel 7 days before neuraxial blockade 3. This timeframe allows for platelet replenishment (which occurs at 10-15% per day) since clopidogrel causes irreversible platelet inhibition 3.
For Lower Bleeding Risk Procedures
Recent evidence suggests these procedures may be performed with clopidogrel continued:
- A retrospective study of 275 spinal injections (including 21 on clopidogrel) showed zero epidural hematomas or serious bleeding complications 5
- Another study of 490 patients on antithrombotics (129 on P2Y12 inhibitors) undergoing low-to-intermediate risk spine procedures found only one minor injection site bleeding in a patient on dual antiplatelet therapy 6
- A prospective study of 197 injection sites in patients on antiplatelet/anticoagulants found no bleeding events for transforaminal, facet, or radiofrequency procedures 7
However, the Canadian Cardiovascular Society guidelines still recommend discontinuing clopidogrel 7-10 days before arthrocentesis (a comparable procedure) if it can be done safely 1, 2.
Clinical Decision Algorithm
Step 1: Identify cardiovascular risk
- If recent stent (<6 weeks BMS, <12 months DES) → Do not stop clopidogrel; consider postponing elective procedure 1, 2
- If other high cardiovascular risk → Cardiology consultation required
Step 2: Classify injection type
- If interlaminar epidural → Must stop clopidogrel 7-10 days (unless cardiovascular risk prohibits)
- If transforaminal/facet/medial branch → May consider continuing with informed consent, though guidelines still favor stopping 1, 2
Step 3: If stopping clopidogrel:
- Discontinue 7-10 days before procedure 1, 2
- If also on aspirin and cardiovascular risk is high, continue aspirin 1, 2
- Resume clopidogrel postoperatively once hemostasis is assured (typically 24-48 hours)
Critical Caveats
Age consideration: At 88 years old, this patient has increased baseline bleeding risk but also likely has significant cardiovascular disease warranting clopidogrel. The risk-benefit calculation is particularly delicate.
Dual antiplatelet therapy: If she's on both aspirin and clopidogrel, the bleeding risk is substantially higher. For high-risk procedures, clopidogrel should be stopped 7-10 days prior while aspirin may be continued if cardiovascular risk is high 1, 2.
Recent case report warning: A 2026 case report documented a retroperitoneal hematoma in a patient on clopidogrel who underwent combined lumbar procedures, resulting in permanent neurologic injury 8. This underscores that even "lower risk" procedures can have catastrophic bleeding complications when antiplatelet therapy is continued.
Bridging is NOT recommended: Unlike anticoagulation, there is no role for bridging antiplatelet therapy with short-acting agents for routine spinal injections 3.
Practical Recommendation
For this 88-year-old patient, the safest approach is to discontinue clopidogrel 7-10 days before the spinal injection unless she has a recent coronary stent or other compelling cardiovascular contraindication to stopping. Coordinate with her cardiologist to assess cardiovascular risk, and if the injection is interlaminar epidural, clopidogrel discontinuation is mandatory unless the cardiovascular risk is prohibitively high, in which case the procedure should be deferred 1, 2, 3, 4.